Trial · NCT07913516
Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
NCT07913516, Not applicable, Not yet recruiting, Huanfang Fan
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer. Trials, record NCT07913516. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913516
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
- NCT number
- NCT07913516
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Huanfang Fan
- Conditions
- Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction
- Interventions
- Capecitabine, Huangqi Yangyuan Formula (Chinese Herbal Decoction)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Completion Rate of Standardized Capecitabine Chemotherapy | At the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Proportion of participants completing 4 cycles and 8 cycles of capecitabine chemotherapy without treatment discontinuation or major dose reduction. |
| Secondary | Incidence and Grade of Chemotherapy-Related Adverse Events | At the baseline, at the end of every 2 chemotherapy cycles (each cycle lasting 28 days), and at the end of the third month after the treatment was completed. | Adverse events graded according to CTCAE version 5.0, including diarrhea, hand-foot reaction, myelosuppression, fatigue, gastrointestinal symptoms, and hepatic/renal toxicity. |
| Secondary | Quality of Life Score (EORTC QLQ-C30) | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) total score and subscale scores. Score range: 0-100. Higher scores represent better quality of life for the global health status/QoL scale and functional scales; higher scores represent worse symptoms for symptom subscales. |
| Secondary | Traditional Chinese Medicine Constitution Score | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | BCQ (Body Constitution Questionnaire) scores for qi deficiency, blood deficiency, and yang deficiency. |
| Secondary | Disease-Free Survival Rate | At the end of the third month after the completion of chemotherapy. | Proportion of participants alive and progression-free at 3 months after completion of chemotherapy |
| Secondary | Peripheral Blood T-Lymphocyte Subsets | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Absolute counts and ratios of CD3+, CD4+, and CD8+ T cells measured by flow cytometry. |
| Secondary | Complete Blood Count | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Check blood routine indicators such as white blood cells, neutrophils, hemoglobin, and platelets. |
| Secondary | Liver Function | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Liver function tests such as Alanine aminotransferase and Aspartate aminotransferase. |
| Secondary | Renal Function | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Testing renal function such as serum creatinine, glomerular filtration rate, and blood urea nitrogen. |
| Secondary | Serum Electrolytes | At baseline, the end of the fourth and eighth cycles of chemotherapy (each cycle is 28 days). | Testing blood electrolyte levels. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913516
GET https://conductscience.org/api/trials/v1/NCT07913516/registered